Article

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

2023-02-06

Abstract excerpt

β-Thalassemia is an inherited hematological disorder that results from genetic changes in the β-globin gene, leading to the reduced or absent synthesis of β-globin. For several decades, the only curative treatment option for β-thalassemia has been allogeneic hematopoietic cell transplantation (allo-HCT). Nonetheless, rapid progress in genome modification technologies holds great potential for treating this disease...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3d94b4dc-0980-5e3b-9965-9593bcd62a66
DOI: 10.3390/thalassrep13010006

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-ThalassemiaDOI 10.3390/thalassrep13010006Read

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read

Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia diseaseSemantic proximity Read

CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.Semantic proximity Read

Recent advancements in gene therapy for sickle cell disease and β-thalassemiaSemantic proximity Read

A Review of Gene Therapies for HemoglobinopathiesSemantic proximity Read

CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.Semantic proximity Read

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read

Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathiesSemantic proximity Read

β-Thalassemia gene editing therapy: Advancements and difficultiesSemantic proximity Read

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current reviewSemantic proximity Read

Novel genetic therapeutic approaches for modulating the severity of β‑thalassemia (Review)Semantic proximity Read